Sign up to save your podcasts
Or
Share Ocular Myasthenia Gravis Gets Its First Targeted Biologic Candidate
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ocular Myasthenia Gravis Gets Its First Targeted Biologic Candidate
New Phase 3 data highlight efgartigimod’s targeted efficacy in ocular myasthenia gravis, signaling a shift toward precision therapies that reduce treatment burden and improve patient-centered outcomes.
View all episodes
By TheBrief.HealthNew Phase 3 data highlight efgartigimod’s targeted efficacy in ocular myasthenia gravis, signaling a shift toward precision therapies that reduce treatment burden and improve patient-centered outcomes.